Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients.
Gespeichert in:
| Autor*in: |
Calabresi, Peter A [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport - Fang, Jun ELSEVIER, 2014transfer abstract, London |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2014 ; number:6 ; pages:545-556 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1474-4422(14)70049-3 |
|---|
| Katalog-ID: |
ELV027901742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV027901742 | ||
| 003 | DE-627 | ||
| 005 | 20230623191750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(14)70049-3 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014004000028.pica |
| 035 | |a (DE-627)ELV027901742 | ||
| 035 | |a (ELSEVIER)S1474-4422(14)70049-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.17 |2 bkl | ||
| 084 | |a 58.50 |2 bkl | ||
| 084 | |a 43.12 |2 bkl | ||
| 100 | 1 | |a Calabresi, Peter A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| 264 | 1 | |c 2014 | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. | ||
| 700 | 1 | |a Radue, Ernst-Wilhelm |4 oth | |
| 700 | 1 | |a Goodin, Douglas |4 oth | |
| 700 | 1 | |a Jeffery, Douglas |4 oth | |
| 700 | 1 | |a Rammohan, Kottil W |4 oth | |
| 700 | 1 | |a Reder, Anthony T |4 oth | |
| 700 | 1 | |a Vollmer, Timothy |4 oth | |
| 700 | 1 | |a Agius, Mark A |4 oth | |
| 700 | 1 | |a Kappos, Ludwig |4 oth | |
| 700 | 1 | |a Stites, Tracy |4 oth | |
| 700 | 1 | |a Li, Bingbing |4 oth | |
| 700 | 1 | |a Cappiello, Linda |4 oth | |
| 700 | 1 | |a von Rosenstiel, Philipp |4 oth | |
| 700 | 1 | |a Lublin, Fred D |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Lancet Publ. Group |a Fang, Jun ELSEVIER |t Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |d 2014transfer abstract |g London |w (DE-627)ELV017537959 |
| 773 | 1 | 8 | |g volume:13 |g year:2014 |g number:6 |g pages:545-556 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1474-4422(14)70049-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 35.17 |j Katalyse |q VZ |
| 936 | b | k | |a 58.50 |j Umwelttechnik: Allgemeines |q VZ |
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2014 |e 6 |h 545-556 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
p a c pa pac |
|---|---|
| matchkey_str |
calabresipeteraradueernstwilhelmgoodindo:2014----:aeynefccofnoioiptetwtrlpigeitnmlilslrssreosidulbida |
| hierarchy_sort_str |
2014 |
| bklnumber |
35.17 58.50 43.12 |
| publishDate |
2014 |
| allfields |
10.1016/S1474-4422(14)70049-3 doi GBVA2014004000028.pica (DE-627)ELV027901742 (ELSEVIER)S1474-4422(14)70049-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial 2014 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Radue, Ernst-Wilhelm oth Goodin, Douglas oth Jeffery, Douglas oth Rammohan, Kottil W oth Reder, Anthony T oth Vollmer, Timothy oth Agius, Mark A oth Kappos, Ludwig oth Stites, Tracy oth Li, Bingbing oth Cappiello, Linda oth von Rosenstiel, Philipp oth Lublin, Fred D oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:6 pages:545-556 extent:12 https://doi.org/10.1016/S1474-4422(14)70049-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 6 545-556 12 045F 610 |
| spelling |
10.1016/S1474-4422(14)70049-3 doi GBVA2014004000028.pica (DE-627)ELV027901742 (ELSEVIER)S1474-4422(14)70049-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial 2014 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Radue, Ernst-Wilhelm oth Goodin, Douglas oth Jeffery, Douglas oth Rammohan, Kottil W oth Reder, Anthony T oth Vollmer, Timothy oth Agius, Mark A oth Kappos, Ludwig oth Stites, Tracy oth Li, Bingbing oth Cappiello, Linda oth von Rosenstiel, Philipp oth Lublin, Fred D oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:6 pages:545-556 extent:12 https://doi.org/10.1016/S1474-4422(14)70049-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 6 545-556 12 045F 610 |
| allfields_unstemmed |
10.1016/S1474-4422(14)70049-3 doi GBVA2014004000028.pica (DE-627)ELV027901742 (ELSEVIER)S1474-4422(14)70049-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial 2014 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Radue, Ernst-Wilhelm oth Goodin, Douglas oth Jeffery, Douglas oth Rammohan, Kottil W oth Reder, Anthony T oth Vollmer, Timothy oth Agius, Mark A oth Kappos, Ludwig oth Stites, Tracy oth Li, Bingbing oth Cappiello, Linda oth von Rosenstiel, Philipp oth Lublin, Fred D oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:6 pages:545-556 extent:12 https://doi.org/10.1016/S1474-4422(14)70049-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 6 545-556 12 045F 610 |
| allfieldsGer |
10.1016/S1474-4422(14)70049-3 doi GBVA2014004000028.pica (DE-627)ELV027901742 (ELSEVIER)S1474-4422(14)70049-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial 2014 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Radue, Ernst-Wilhelm oth Goodin, Douglas oth Jeffery, Douglas oth Rammohan, Kottil W oth Reder, Anthony T oth Vollmer, Timothy oth Agius, Mark A oth Kappos, Ludwig oth Stites, Tracy oth Li, Bingbing oth Cappiello, Linda oth von Rosenstiel, Philipp oth Lublin, Fred D oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:6 pages:545-556 extent:12 https://doi.org/10.1016/S1474-4422(14)70049-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 6 545-556 12 045F 610 |
| allfieldsSound |
10.1016/S1474-4422(14)70049-3 doi GBVA2014004000028.pica (DE-627)ELV027901742 (ELSEVIER)S1474-4422(14)70049-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Calabresi, Peter A verfasserin aut Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial 2014 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Radue, Ernst-Wilhelm oth Goodin, Douglas oth Jeffery, Douglas oth Rammohan, Kottil W oth Reder, Anthony T oth Vollmer, Timothy oth Agius, Mark A oth Kappos, Ludwig oth Stites, Tracy oth Li, Bingbing oth Cappiello, Linda oth von Rosenstiel, Philipp oth Lublin, Fred D oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:13 year:2014 number:6 pages:545-556 extent:12 https://doi.org/10.1016/S1474-4422(14)70049-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 13 2014 6 545-556 12 045F 610 |
| language |
English |
| source |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:13 year:2014 number:6 pages:545-556 extent:12 |
| sourceStr |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:13 year:2014 number:6 pages:545-556 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Katalyse Umwelttechnik: Allgemeines Umweltchemie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| authorswithroles_txt_mv |
Calabresi, Peter A @@aut@@ Radue, Ernst-Wilhelm @@oth@@ Goodin, Douglas @@oth@@ Jeffery, Douglas @@oth@@ Rammohan, Kottil W @@oth@@ Reder, Anthony T @@oth@@ Vollmer, Timothy @@oth@@ Agius, Mark A @@oth@@ Kappos, Ludwig @@oth@@ Stites, Tracy @@oth@@ Li, Bingbing @@oth@@ Cappiello, Linda @@oth@@ von Rosenstiel, Philipp @@oth@@ Lublin, Fred D @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV017537959 |
| dewey-sort |
3610 |
| id |
ELV027901742 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027901742</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623191750.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(14)70049-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027901742</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(14)70049-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Calabresi, Peter A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Radue, Ernst-Wilhelm</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodin, Douglas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jeffery, Douglas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rammohan, Kottil W</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reder, Anthony T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vollmer, Timothy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Agius, Mark A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kappos, Ludwig</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stites, Tracy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Bingbing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cappiello, Linda</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Rosenstiel, Philipp</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lublin, Fred D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:545-556</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(14)70049-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2014</subfield><subfield code="e">6</subfield><subfield code="h">545-556</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Calabresi, Peter A |
| spellingShingle |
Calabresi, Peter A ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| authorStr |
Calabresi, Peter A |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV017537959 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| topic |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_unstemmed |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_browse |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e w r ewr d g dg d j dj k w r kw kwr a t r at atr t v tv m a a ma maa l k lk t s ts b l bl l c lc r p v rp rpv f d l fd fdl |
| hierarchy_parent_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| hierarchy_parent_id |
ELV017537959 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV017537959 |
| title |
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| ctrlnum |
(DE-627)ELV027901742 (ELSEVIER)S1474-4422(14)70049-3 |
| title_full |
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| author_sort |
Calabresi, Peter A |
| journal |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| journalStr |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
545 |
| author_browse |
Calabresi, Peter A |
| container_volume |
13 |
| physical |
12 |
| class |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Calabresi, Peter A |
| doi_str_mv |
10.1016/S1474-4422(14)70049-3 |
| dewey-full |
610 570 540 |
| title_sort |
safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (freedoms ii): a double-blind, randomised, placebo-controlled, phase 3 trial |
| title_auth |
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| abstract |
Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. |
| abstractGer |
Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. |
| abstract_unstemmed |
Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 |
| container_issue |
6 |
| title_short |
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial |
| url |
https://doi.org/10.1016/S1474-4422(14)70049-3 |
| remote_bool |
true |
| author2 |
Radue, Ernst-Wilhelm Goodin, Douglas Jeffery, Douglas Rammohan, Kottil W Reder, Anthony T Vollmer, Timothy Agius, Mark A Kappos, Ludwig Stites, Tracy Li, Bingbing Cappiello, Linda von Rosenstiel, Philipp Lublin, Fred D |
| author2Str |
Radue, Ernst-Wilhelm Goodin, Douglas Jeffery, Douglas Rammohan, Kottil W Reder, Anthony T Vollmer, Timothy Agius, Mark A Kappos, Ludwig Stites, Tracy Li, Bingbing Cappiello, Linda von Rosenstiel, Philipp Lublin, Fred D |
| ppnlink |
ELV017537959 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1474-4422(14)70049-3 |
| up_date |
2024-07-06T17:25:34.324Z |
| _version_ |
1803851382732619776 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027901742</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623191750.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(14)70049-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027901742</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(14)70049-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Calabresi, Peter A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Radue, Ernst-Wilhelm</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodin, Douglas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jeffery, Douglas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rammohan, Kottil W</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reder, Anthony T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vollmer, Timothy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Agius, Mark A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kappos, Ludwig</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stites, Tracy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Bingbing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cappiello, Linda</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Rosenstiel, Philipp</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lublin, Fred D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:545-556</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(14)70049-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2014</subfield><subfield code="e">6</subfield><subfield code="h">545-556</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402273 |